title: Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.
abstract: Viral resistance to small molecule allosteric inhibitors of CCR5 is well documented, and involves either selection of preexisting CXCR4-using HIV-1 variants or envelope sequence evolution to use inhibitor-bound CCR5 for entry. Resistance to macromolecular CCR5 inhibitors has been more difficult to demonstrate, although selection of CXCR4-using variants might be expected. We have compared the in vitro selection of HIV-1 CC1/85 variants resistant to either the small molecule inhibitor maraviroc (MVC) or the macromolecular inhibitor 5P12-RANTES. High level resistance to MVC was conferred by the same envelope mutations as previously reported after 16-18 weeks of selection by increasing levels of MVC. The MVC-resistant mutants were fully sensitive to inhibition by 5P12-RANTES. By contrast, only transient and low level resistance to 5P12-RANTES was achieved in three sequential selection experiments, and each resulted in a subsequent collapse of virus replication. A fourth round of selection by 5P12-RANTES led, after 36 weeks, to a "resistant" variant that had switched from CCR5 to CXCR4 as a coreceptor. Envelope sequences diverged by 3.8% during selection of the 5P12-RANTES resistant, CXCR4-using variants, with unique and critical substitutions in the V3 region. A subset of viruses recovered from control cultures after 44 weeks of passage in the absence of inhibitors also evolved to use CXCR4, although with fewer and different envelope mutations. Control cultures contained both viruses that evolved to use CXCR4 by deleting four amino acids in V3, and others that maintained entry via CCR5. These results suggest that coreceptor switching may be the only route to resistance for compounds like 5P12-RANTES. This pathway requires more mutations and encounters more fitness obstacles than development of resistance to MVC, confirming the clinical observations that resistance to small molecule CCR5 inhibitors very rarely involves coreceptor switching.
authors.affiliation: Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Nedellec
authors.forename: Mia
authors.initials: M
authors.lastname: Coetzer
authors.forename: Michael M
authors.initials: MM
authors.lastname: Lederman
authors.forename: Robin E
authors.initials: RE
authors.lastname: Offord
authors.forename: Oliver
authors.initials: O
authors.lastname: Hartley
authors.forename: Donald E
authors.initials: DE
authors.lastname: Mosier
mesh_terms: D000595:Amino Acid Sequence; D065100:CCR5 Receptor Antagonists; D019742:Chemokines, CC / Q000494:pharmacology*; D003510:Cyclohexanes / Q000494:pharmacology; D019020:Directed Molecular Evolution; D024882:Drug Resistance, Viral / Q000187:drug effects*; D019302:HIV Envelope Protein gp160 / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006801:Humans; D000077592:Maraviroc; D008969:Molecular Sequence Data; D019713:Receptors, CCR5 / Q000737:chemistry / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000737:chemistry / Q000378:metabolism*; D014230:Triazoles / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects
chemical_list: C539265:5P12-RANTES; D065100:CCR5 Receptor Antagonists; D019742:Chemokines, CC; D003510:Cyclohexanes; D019302:HIV Envelope Protein gp160; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; D014230:Triazoles; D000077592:Maraviroc